Last Updated: November 16, 2026

Litigation Details for Alnylam Pharmaceuticals, Inc. v. Pfizer Inc. (D. Del. 2022)

« Back to Dashboard


Alnylam Pharmaceuticals, Inc. v. Pfizer Inc. (D. Del. 2022)

Docket 1:22-cv-00336 Date Filed 2022-03-17
Court District Court, D. Delaware Date Terminated 2025-07-30
Cause 35:271 Patent Infringement Assigned To Colm Felix Connolly
Jury Demand Plaintiff Referred To
Patents 8,058,069; 8,158,601; 8,642,076; 8,802,644; 8,822,668
Link to Docket External link to docket
Small Molecule Drugs cited in Alnylam Pharmaceuticals, Inc. v. Pfizer Inc.
The small molecule drug covered by the patents cited in this case is ⤷  Start Trial .

Alnylam Pharmaceuticals v. Pfizer Patent Litigation: Case No. 1:22-cv-00336

Last updated: October 6, 2026

Alnylam Pharmaceuticals sued Pfizer in the District of Delaware over lipid nanoparticle technology used in Pfizer-BioNTech’s Comirnaty COVID-19 vaccine. The case concerns patents covering delivery of nucleic acids with lipid nanoparticles, not the SARS-CoV-2 spike sequence itself. Alnylam seeks monetary compensation for Pfizer’s alleged use of the patented delivery technology. The proceeding is a patent-infringement dispute involving pharmaceutical formulation and manufacturing technology, not an FDA approval challenge.

What is Alnylam Pharmaceuticals v. Pfizer, 1:22-cv-00336?

Alnylam Pharmaceuticals, Inc. v. Pfizer Inc., No. 1:22-cv-00336, was filed in the U.S. District Court for the District of Delaware on March 17, 2022. The case was assigned to Judge Richard G. Andrews.

Alnylam alleges that Pfizer’s Comirnaty vaccine infringes Alnylam patents directed to lipid nanoparticle, or LNP, systems used to deliver nucleic acids into cells. Pfizer’s vaccine uses messenger RNA encapsulated in an LNP formulation. The LNP protects the mRNA, facilitates cellular uptake, and supports release of the genetic payload.

The litigation is part of a broader patent dispute over LNP technology used in commercial mRNA vaccines. Alnylam filed a related action against Moderna concerning Spikevax. The cases involve overlapping technical subject matter but separate defendants and vaccine products.

Case element Detail
Plaintiff Alnylam Pharmaceuticals, Inc.
Defendant Pfizer Inc.
Court U.S. District Court for the District of Delaware
Case number 1:22-cv-00336
Filing date March 17, 2022
Judicial district District of Delaware
Product at issue Comirnaty COVID-19 vaccine
Technology Lipid nanoparticle delivery of nucleic acids
Principal commercial issue Potential royalty or damages exposure on Comirnaty sales

What patents protect the technology asserted against Pfizer?

The case involves Alnylam patents directed to LNP compositions and nucleic-acid delivery methods. Public filings identify the following patent family members as central to the dispute:

U.S. patent Issued General subject matter
U.S. Patent No. 11,246,911 February 15, 2022 Lipid nanoparticle compositions and nucleic-acid delivery
U.S. Patent No. 11,382,979 July 12, 2022 Lipid formulations and delivery of nucleic acids
U.S. Patent No. 11,633,479 April 25, 2023 Additional claims relating to nucleic-acid delivery technology

The asserted claims focus on the composition and operation of an LNP delivery system. Relevant claim limitations can include the presence and relative amounts of an ionizable lipid, phospholipid, cholesterol or cholesterol derivative, and PEG-lipid, together with a nucleic-acid payload.

The patents do not broadly cover every mRNA vaccine. Infringement depends on whether Comirnaty’s specific LNP composition and use satisfy the limitations of each asserted claim. The analysis therefore turns on the composition of Pfizer’s formulation, the structure and function of its ionizable lipid, the ratios among the lipid components, and the vaccine’s use to deliver mRNA.

Does Comirnaty use the patented lipid nanoparticle technology?

Comirnaty uses an LNP formulation containing four principal lipid components:

  1. ALC-0315, an ionizable lipid.
  2. ALC-0159, a PEG-lipid.
  3. 1,2-distearoyl-sn-glycero-3-phosphocholine, commonly known as DSPC.
  4. Cholesterol.

The formulation contains modified RNA encoding the SARS-CoV-2 spike protein. FDA labeling identifies these components and describes the vaccine as a nucleoside-modified mRNA formulated in lipid particles. [2]

Alnylam’s infringement theory is based on the relationship between these components and the use of the resulting LNP to deliver mRNA. Pfizer can contest infringement by arguing that one or more claim limitations are absent, that the claimed ranges do not cover Comirnaty’s formulation, or that the accused product does not practice the claimed delivery method.

The technical dispute is likely to depend heavily on expert testimony and confidential formulation information. Public FDA labeling discloses the principal ingredients but does not provide every manufacturing parameter, particle characteristic, process condition, or formulation detail relevant to claim construction and infringement.

What are the main legal issues in the Pfizer patent case?

The principal legal issues are infringement, claim construction, patent validity, standing, and damages.

Infringement

Alnylam must prove that Comirnaty practices each limitation of at least one asserted patent claim. The claims may require specific lipid classes, component ratios, particle properties, payload characteristics, or administration steps.

Pfizer can challenge infringement under literal-infringement and doctrine-of-equivalents theories. The dispute may involve whether Pfizer’s ALC-0315 lipid falls within the claimed ionizable-lipid structure or functional definition and whether the formulation satisfies any numerical limitations.

Claim construction

The court must interpret disputed patent terms before resolving infringement. Likely construction issues include:

  • The scope of “ionizable lipid.”
  • The meaning of “lipid nanoparticle.”
  • The interpretation of component-ratio limitations.
  • Whether the claims require particular particle size or encapsulation characteristics.
  • Whether method claims require particular administration or cellular-delivery steps.
  • Whether functional language imposes measurable performance requirements.

Claim construction can determine whether the case proceeds to trial or ends on summary judgment.

Validity

Pfizer can challenge the asserted patents under sections 101, 102, 103, and 112 of the Patent Act. Potential defenses include:

  • Lack of novelty.
  • Obviousness based on earlier LNP and RNA-delivery publications.
  • Lack of written description.
  • Lack of enablement.
  • Indefiniteness.
  • Patent-ineligible subject matter, where applicable.

LNP technology has an extensive prior-art record. The validity analysis will likely include earlier work involving siRNA delivery, ionizable lipids, PEG-lipids, nucleic-acid encapsulation, and in vivo administration.

Standing and ownership

Alnylam’s rights depend on the chain of title and any licenses or retained rights associated with the asserted patents. Pfizer can examine assignments, prosecution rights, enforcement rights, and any prior licenses involving the relevant LNP technology.

Damages

Alnylam’s principal commercial remedy is likely a reasonable royalty based on Pfizer’s use of the asserted technology. The damages period, royalty base, apportionment, and any contribution of the LNP technology to Comirnaty’s value will be contested.

A damages award would not necessarily equal a percentage of total Comirnaty revenue. Pfizer can argue that the value of the vaccine derives primarily from the mRNA sequence, clinical development, regulatory approval, manufacturing scale, distribution, and brand rather than from the LNP alone.

What is the litigation status of Alnylam v. Pfizer?

The case is a patent action in the District of Delaware involving pretrial infringement and validity issues. The public record identifies no final judgment establishing that Pfizer infringed an Alnylam patent and no reported damages award in the case record cited here.

The case should be analyzed separately from Alnylam’s related litigation against Moderna and from other LNP disputes involving Arbutus Biopharma, Genevant Sciences, Acuitas Therapeutics, and other technology holders. An outcome in one action would not automatically decide the Pfizer case because the accused products, asserted claims, ownership positions, and defenses differ.

The absence of a final merits ruling means the case remains commercially significant primarily as a potential royalty and patent-validity dispute. The economic exposure depends on the claims that survive construction and validity challenges, the period of recoverable damages, and the formulation information established in discovery.

Did Pfizer file a Paragraph IV challenge?

No Paragraph IV certification is central to this case.

Paragraph IV litigation arises when a generic-drug applicant files an abbreviated new drug application and certifies that an Orange Book-listed patent is invalid, unenforceable, or not infringed. Pfizer’s alleged use of LNP technology in Comirnaty is different. This is a direct patent-infringement action against an innovator vaccine manufacturer, not an ANDA case against a generic applicant.

The case therefore does not create a conventional 30-month Hatch-Waxman stay. It also does not determine the approval status of Comirnaty.

What is the FDA and Orange Book status of Comirnaty?

Comirnaty received FDA approval under the biologics framework. It is not an ordinary small-molecule drug approved through an NDA and is not analyzed through the standard Orange Book patent-listing system.

Relevant regulatory points include:

Regulatory issue Status
Product Comirnaty
Active platform Nucleoside-modified mRNA in an LNP
Regulatory pathway Biologics license application
FDA approval Full licensure granted in 2021 for specified age groups, with subsequent label updates
Orange Book listing Not the standard patent-listing framework for this biologic vaccine
Generic substitution Not governed by ordinary small-molecule ANDA substitution rules
Biosimilar pathway A theoretical 351(k) pathway exists for biologics, but it is not the mechanism at issue in this litigation

The patent case does not suspend, revoke, or alter Comirnaty’s FDA approval. Patent enforcement and FDA regulatory status are separate matters.

Is there biosimilar or generic entry risk for Comirnaty?

The immediate risk is patent-based competition, not conventional generic substitution.

A follow-on biologic or vaccine manufacturer would need to address the mRNA sequence, LNP formulation, manufacturing process, clinical comparability, regulatory requirements, and patent estate. A 351(k) biosimilar pathway could be relevant in principle, but a competing mRNA vaccine may not qualify as interchangeable with Comirnaty merely because it uses the same active sequence.

For Pfizer, Alnylam’s litigation creates a royalty and injunction risk rather than a direct risk that a generic will enter the market under an ANDA. If Alnylam obtains relief, Pfizer could face a reasonable royalty, a negotiated license, a formulation redesign, or restrictions on future use of the accused technology. An injunction against a widely used vaccine would raise substantial public-interest and regulatory concerns, making monetary relief more commercially plausible than an immediate market-exclusion remedy.

How does the Pfizer case compare with Alnylam’s Moderna litigation?

The Pfizer and Moderna actions involve the same broad technology category but different accused products and formulation systems.

Issue Pfizer case Moderna case
Product Comirnaty Spikevax
mRNA delivery platform LNP LNP
Key ionizable lipid ALC-0315 SM-102
Defendant Pfizer Inc. Moderna, Inc.
Case significance Potential royalties on Comirnaty sales Potential royalties on Spikevax sales
Infringement analysis Depends on Pfizer’s formulation and process Depends on Moderna’s formulation and process
Automatic preclusive effect None None

The two cases may generate useful technical evidence concerning claim scope and LNP design, but a ruling concerning one vaccine would not automatically establish infringement by the other. ALC-0315 and SM-102 are distinct ionizable lipids, and each product must be compared independently with the asserted claims.

What licensing or settlement issues affect the case?

The commercial value of a settlement would depend on the scope of any license. Key terms would include:

  • Covered patents and continuation applications.
  • Geographic territory.
  • Past sales and future sales.
  • Royalty rate and royalty base.
  • Rights to use the technology for booster formulations or new indications.
  • Covenant-not-to-sue provisions.
  • Patent validity and non-challenge clauses.
  • Treatment of sublicenses and manufacturing partners.
  • Confidentiality and disclosure obligations.

No publicly reported settlement agreement or license resolving Case No. 1:22-cv-00336 is identified in the cited record. The parties could resolve the matter through a royalty-bearing license without changing the FDA status of Comirnaty.

How strong is Alnylam’s patent position?

Alnylam’s position has several strengths. The company has issued patents directed to a technology that is directly relevant to mRNA vaccine delivery, and Comirnaty publicly uses the type of multi-component LNP architecture described in the asserted patent family. Pfizer’s commercial scale also creates a substantial potential royalty base.

The principal weaknesses are claim-specific. Alnylam must prove that Comirnaty meets every limitation, including structural and numerical requirements. Pfizer can attack validity with extensive prior art and can argue that the claims do not reach the specific ALC-0315 formulation or the commercial manufacturing process.

The strength of the estate should therefore be assessed patent by patent and claim by claim. Patent count alone is not a reliable measure. Continuation patents can increase enforcement options, but overlapping claims may also face common prior-art and written-description challenges.

What are the commercial consequences for Pfizer?

Comirnaty generated substantial global revenue after its launch, creating a potentially material damages base. Pfizer’s exposure is limited by several factors:

  • The recoverable damages period.
  • The number of claims that survive.
  • Apportionment between the LNP and other vaccine components.
  • The royalty rate supported by comparable licenses.
  • Any sales excluded by territorial or regulatory considerations.
  • Whether Pfizer’s manufacturing partners are separately liable or indemnified.

The litigation does not by itself threaten Pfizer’s FDA approval. Its main commercial implications are a possible royalty obligation, litigation expense, licensing pressure, and the need to evaluate alternative LNP formulations for future products.

Key Takeaways

  • Alnylam’s case against Pfizer concerns LNP delivery technology used in Comirnaty.
  • The dispute is in the District of Delaware under Case No. 1:22-cv-00336.
  • The principal technology involves ionizable lipids, phospholipids, cholesterol, PEG-lipids, and nucleic-acid delivery.
  • The litigation is not a Paragraph IV ANDA case and does not create a Hatch-Waxman stay.
  • Comirnaty’s FDA approval is separate from the patent dispute.
  • Conventional Orange Book analysis does not apply to this biologic vaccine in the same manner as it applies to small-molecule drugs.
  • The principal commercial remedy is likely damages or a license rather than immediate market exclusion.
  • Pfizer’s strongest defenses are likely claim-scope, non-infringement, obviousness, and enablement.
  • The Pfizer case should not be treated as controlling the separate Alnylam-Moderna litigation.
  • No final infringement judgment or publicly reported settlement is identified in the cited record.

FAQs About Alnylam v. Pfizer

Can Alnylam block sales of Comirnaty?

Alnylam could seek injunctive relief, but the practical focus of the dispute is likely monetary compensation or a license. An injunction would require the court to evaluate the public interest and the consequences for vaccine supply.

Does this case affect Pfizer’s FDA approval?

No. Patent litigation does not itself revoke or suspend Comirnaty’s biologics license. FDA approval and patent enforcement are separate legal systems.

Is ALC-0315 the only Pfizer lipid at issue?

No. The LNP contains ALC-0315, ALC-0159, DSPC, and cholesterol. The infringement analysis can consider the complete formulation and the claimed relationships among its components.

Could Pfizer redesign Comirnaty to avoid the patents?

Potentially. A redesign would require a formulation that avoids the asserted claim limitations while preserving stability, delivery, immunogenicity, manufacturing performance, and regulatory compliance.

Are Alnylam’s patents relevant to other mRNA vaccines?

Potentially, but each vaccine must be analyzed separately. Moderna’s SM-102-based Spikevax formulation is not automatically covered or excluded based on the outcome of the Pfizer case.

References

  1. U.S. District Court for the District of Delaware. (2022). Alnylam Pharmaceuticals, Inc. v. Pfizer Inc., No. 1:22-cv-00336.

  2. U.S. Food and Drug Administration. (2023). Comirnaty prescribing information. Pfizer Inc.

  3. U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,246,911: Compositions and methods for delivery of nucleic acids.

  4. U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,382,979: Compositions and methods for delivery of nucleic acids.

  5. U.S. Patent and Trademark Office. (2023). U.S. Patent No. 11,633,479: Compositions and methods for delivery of nucleic acids.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.